Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102702178B details a novel Lapatinib synthesis using THP protection for improved solubility and cost reduction in API manufacturing supply chains.
Advanced synthesis of 4'-norepipodophyllotoxin derivatives via patent CN101074233B. Overcoming drug resistance with high-yield, scalable pharmaceutical intermediate production.
Patent CN101602707A details novel naphthalenolactam synthesis. Offers high-purity intermediates for tumor proliferation inhibition studies with scalable routes.
Patent CN111349081B reveals a chiral protonic acid catalyzed Ugi reaction for Ivosidenib, eliminating chiral columns and toxic solvents for scalable manufacturing.
Discover a novel Pd-catalyzed synthesis for seven-membered indoloazepine CYP1B1 inhibitors. Efficient route, broad substrate scope, and scalable manufacturing for pharmaceutical applications.
Advanced decitabine synthesis patent analysis reveals improved purity and yield for pharmaceutical intermediate supply chains reducing costs.
Patent CN110944974B details a novel oleum-based nitration process for 5-fluoro-2-methyl-3-nitrobenzoic acid, offering superior yield and purity for PARP inhibitor manufacturing.
Patent CN111620860B reveals a streamlined synthesis for Afuresertib, eliminating complex protection steps for significant cost reduction and supply chain reliability in AKT inhibitor manufacturing.
Patent CN118791500B reveals stable PP5 inhibitors. Enhances supply chain reliability and cost reduction in API manufacturing for oncology.
Discover high-purity pyrimido[1,2,4]-triazole hydrazine compounds for anticancer drug development. Our patented synthesis offers cost reduction in pharmaceutical intermediate manufacturing.
Advanced low-cost synthesis route for EGFR inhibitor intermediates like Gefitinib and Erlotinib via optimized nitration and cyclization strategies.
Novel Rh-catalyzed one-pot route for spiro-oxindoles. High yield, mild conditions. Reliable pharmaceutical intermediate supplier for oncology drug development.
Discover advanced synthesis of 4-phenoxyquinoline α-acyloxyamides via Passerini reaction. Reliable supplier for high-purity c-Met inhibitors with scalable manufacturing.
Advanced semi-synthetic route for Paclitaxel using CeCl3 catalysis. High-yield process suitable for industrial scale-up and cost-effective API manufacturing.
Patent CN109678853B reveals a green one-pot dasatinib synthesis using ionic liquids, offering high purity and cost reduction for pharmaceutical manufacturing supply chains.
Patent CN111777576A reveals a safer, high-purity synthesis route for Nintedanib key intermediates, offering significant cost reduction and supply chain reliability for API manufacturers.
Patent CN102180836B reveals a safer, cost-effective method for synthesizing kinase inhibitor intermediates, offering significant supply chain advantages.
Patent CN112142804B reveals a novel decitabine preparation method using supercritical fluid separation, offering high purity and reduced solvent consumption for pharmaceutical manufacturing.
Novel patent CN111454217A details a green Rh-catalyzed route for Avapritinib intermediates, offering safer chiral induction and scalable manufacturing for global supply chains.
Patent CN1013440B details a novel chiral pool synthesis for unnatural ceramides, offering high-purity intermediates for ganglioside manufacturing with improved supply chain reliability.